Charles River Acquires WuXi PharmaTech

To read the full article, please choose one of the following options:

US-based clinical research organisation (CRO) Charles River Laboratories has acquired laboratory services firm WuXi PharmaTech for US$1.6bn in cash and stock. CFW expects the combined company to be a success because it is the first fully integrated, global early-stage CRO. This gives it numerous advantages over smaller rivals with fewer resources. We also note that the deal adheres to three of our core views for the pharmaceuticals and healthcare industry.